Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes

BMC Cancer

Research Article

Wen-Chen Tsai¹  Shwn-Huey Shieh²  Janice C Probst³  Ya-Shin Li⁴  Fung-Chang Sung⁵  Chih-Yi Chen⁶ 

[1] Department of Health Services Administration, China Medical University, 40402, Taichung, Taiwan;Department of Health Services Administration, China Medical University, 40402, Taichung, Taiwan;Department of Nursing, China Medical University Hospital, 40402, Taichung, Taiwan;Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA;Department of Health Systems Management, Chung-Shan Medical University and Hospital, 40201, Taichung, Taiwan;Department of Public Health, China Medical University, 40402, Taichung, Taiwan;Department of Medical Research, China Medical University Hospital, 40402, Taichung, Taiwan;Department of Respiratory Therapy, China Medical University, 40402, Taichung, Taiwan;Cancer center, China Medical University Hospital, 2 Yu Der Road, 40402, Taichung, Taiwan;

关键词: Lung cancer;    Comorbidity;    Diabetes;    Survival;    Tuberculosis;   

DOI  :  10.1186/1471-2407-12-174

 received in 2011-10-07, accepted in 2012-05-11,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundComorbid conditions influence the survival of cancer patients. This study evaluated the influence of comorbidity on survival among lung cancer patients.MethodsThe authors evaluated the medical records of 1111 lung cancer patients of a medical center in Taiwan. Days of survival were calculated for each patient and mortality hazard ratios were estimated for associations with demographic status, comorbidity and cancer stage at diagnosis.ResultsOn average, the survival time was slightly longer among women than among men (838 ± 689 vs. 749 ± 654 days, p = 0.050). Survival days increased with age (from 580 ± 526 [≤ 50 years] to 803 ± 693 [≥ 71 years] days, p = 0.020) and decreased with stage (from 1224 ± 656 [stage I] to 489 ± 536 [stage IV] days, p < 0.001). Younger patients were more likely to be diagnosed with lung cancer at a late stage. Compared with lung cancer patients without tuberculosis, those with tuberculosis had a significantly shorter average survival duration (584 vs. 791 days, p = 0.002) and a higher mortality hazard ratio (1.30, 95% CI: 1.03 - 1.65). A similar trend was observed in lung cancer patients with diabetes.ConclusionsLung cancer patients with comorbid tuberculosis or diabetes are at an elevated risk of mortality. These patients deserve greater attention while undergoing cancer treatment.

【 授权许可】

Unknown   
© Shieh et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.